[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1365762T3 - Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser - Google Patents

Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser

Info

Publication number
DK1365762T3
DK1365762T3 DK02721337T DK02721337T DK1365762T3 DK 1365762 T3 DK1365762 T3 DK 1365762T3 DK 02721337 T DK02721337 T DK 02721337T DK 02721337 T DK02721337 T DK 02721337T DK 1365762 T3 DK1365762 T3 DK 1365762T3
Authority
DK
Denmark
Prior art keywords
nicotinic acid
leptin levels
acid compounds
increasing leptin
increase
Prior art date
Application number
DK02721337T
Other languages
English (en)
Inventor
Elaine Jacobson
Myron K Jacobson
Hyuntae Kim
Original Assignee
Univ Kentucky Res Found
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23047813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1365762(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kentucky Res Found, Univ Arizona filed Critical Univ Kentucky Res Found
Application granted granted Critical
Publication of DK1365762T3 publication Critical patent/DK1365762T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK02721337T 2001-03-08 2002-03-08 Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser DK1365762T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27434901P 2001-03-08 2001-03-08
PCT/US2002/007256 WO2002072092A1 (en) 2001-03-08 2002-03-08 Method for increasing leptin levels using nicotinic acid compounds

Publications (1)

Publication Number Publication Date
DK1365762T3 true DK1365762T3 (da) 2008-11-17

Family

ID=23047813

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02721337T DK1365762T3 (da) 2001-03-08 2002-03-08 Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser

Country Status (13)

Country Link
US (2) US6750234B2 (da)
EP (1) EP1365762B1 (da)
JP (1) JP5057353B2 (da)
CN (1) CN1265792C (da)
AT (1) ATE409037T1 (da)
CA (1) CA2437844C (da)
DE (1) DE60229041D1 (da)
DK (1) DK1365762T3 (da)
ES (1) ES2315358T3 (da)
HK (1) HK1065941A1 (da)
MX (1) MXPA03008096A (da)
PT (1) PT1365762E (da)
WO (1) WO2002072092A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154210A0 (en) 2000-07-31 2003-07-31 Univ Bar Ilan Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
JP5057353B2 (ja) * 2001-03-08 2012-10-24 ユニバーシティー オブ ケンタッキー リサーチ ファウンデイション ニコチン酸化合物を使用するレプチンレベル増大のための方法
AU2003299568B2 (en) * 2002-11-27 2010-07-22 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
US8811348B2 (en) 2003-02-24 2014-08-19 Qualcomm Incorporated Methods and apparatus for generating, communicating, and/or using information relating to self-noise
US7218948B2 (en) 2003-02-24 2007-05-15 Qualcomm Incorporated Method of transmitting pilot tones in a multi-sector cell, including null pilot tones, for generating channel quality indicators
US9544860B2 (en) 2003-02-24 2017-01-10 Qualcomm Incorporated Pilot signals for use in multi-sector cells
CN102120031B (zh) 2003-08-07 2012-12-05 希尔洛有限公司 用于加速伤口愈合的药物组合物和方法
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US8503938B2 (en) 2004-10-14 2013-08-06 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information including loading factors which can be used for interference control purposes
RU2007117711A (ru) 2004-10-14 2008-11-20 Квэлкомм Флэрион Текнолоджиз, Инк. (Us) Способы и устройство для определения, передачи и использования информации, которая может быть использована для целей управления помехами
JP2006253769A (ja) * 2005-03-08 2006-09-21 National Institute Of Advanced Industrial & Technology 情報処理システムおよび方法
SI1898867T1 (en) * 2005-06-24 2018-03-30 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona A method for treating hair growth disorders, such as a female pattern of alopecia and the compositions to be used
AU2006286152B2 (en) 2005-08-29 2012-05-31 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US8694042B2 (en) 2005-10-14 2014-04-08 Qualcomm Incorporated Method and apparatus for determining a base station's transmission power budget
US9191840B2 (en) 2005-10-14 2015-11-17 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information which can be used for interference control
US9119220B2 (en) 2005-12-22 2015-08-25 Qualcomm Incorporated Methods and apparatus for communicating backlog related information
US9125092B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus for reporting and/or using control information
US9572179B2 (en) 2005-12-22 2017-02-14 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US7801589B2 (en) 2005-12-22 2010-09-21 Olympus Corporation In-vivo examination method and in-vivo examination apparatus
US9473265B2 (en) 2005-12-22 2016-10-18 Qualcomm Incorporated Methods and apparatus for communicating information utilizing a plurality of dictionaries
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US9137072B2 (en) 2005-12-22 2015-09-15 Qualcomm Incorporated Methods and apparatus for communicating control information
US9338767B2 (en) 2005-12-22 2016-05-10 Qualcomm Incorporated Methods and apparatus of implementing and/or using a dedicated control channel
US8514771B2 (en) 2005-12-22 2013-08-20 Qualcomm Incorporated Methods and apparatus for communicating and/or using transmission power information
US20070249360A1 (en) 2005-12-22 2007-10-25 Arnab Das Methods and aparatus related to determining, communicating, and/or using delay information in a wireless communications system
US9451491B2 (en) 2005-12-22 2016-09-20 Qualcomm Incorporated Methods and apparatus relating to generating and transmitting initial and additional control information report sets in a wireless system
US9125093B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus related to custom control channel reporting formats
US9148795B2 (en) 2005-12-22 2015-09-29 Qualcomm Incorporated Methods and apparatus for flexible reporting of control information
US20070243882A1 (en) 2006-04-12 2007-10-18 Qualcomm Incorporated Method and apparatus for locating a wireless local area network associated with a wireless wide area network
WO2008026349A1 (fr) * 2006-08-31 2008-03-06 Juridical Foundation Osaka Industrial Promotion Organization Agent thérapeutique destiné au traitement de l'effluvium télogène
DK2120917T3 (da) * 2007-02-28 2014-04-07 Univ Kentucky Res Found Fremgangsmåde til lindring af bivirkninger ved retinsyre-terapi og/eller til forbedring af effektivitet uden at interferere med effektiviteten
CN103083669A (zh) 2010-01-11 2013-05-08 希尔洛有限公司 用于治疗炎性疾病和病症的方法
CN118873522A (zh) * 2016-04-22 2024-11-01 无锡杰西医药股份有限公司 异硫氰酸酯类化合物的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505896A (en) * 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
DE3110611A1 (de) * 1981-03-18 1982-10-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "mitogene der leukozyten und des entzuendungsgewebes:natuerliche leukopoetine zur selektiven anregung der teilung und differenzierung von leukozyten"
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
EP0182635B1 (en) * 1984-11-15 1989-05-31 Nitto Denko Corporation Composition for percutaneous administration
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
JP2657583B2 (ja) * 1991-03-01 1997-09-24 ユニバーシテイ オブ フロリダ リサーチ ファンデーション インコーポレイテッド 神経系変性疾患の治療に対するニコチン類似体の利用
US5240945A (en) * 1992-02-18 1993-08-31 Warshaw Thelma G Method and compositions for treating acne
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
CA2215387A1 (en) * 1995-03-20 1996-09-26 Michael R. Briggs Modulators of ob gene and screening methods therefor
CA2220091C (en) * 1995-05-01 2011-01-04 Scotia Holdings Plc Nicotinic acid esters and pharmaceutical compositions containing them
WO1998052927A1 (en) * 1997-05-19 1998-11-26 Rosemarie Scivoletto Composition for treating skin conditions
WO1999059614A1 (en) * 1998-05-20 1999-11-25 Yale University Modulation of angiogenesis and wound healing
AR023715A1 (es) * 1998-12-01 2002-09-04 Univ Kentucky Res Found Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US6326034B1 (en) * 1999-12-22 2001-12-04 Natural Compounds Ltd Natural extracted and synthetic antioxidant compositions
JP5057353B2 (ja) * 2001-03-08 2012-10-24 ユニバーシティー オブ ケンタッキー リサーチ ファウンデイション ニコチン酸化合物を使用するレプチンレベル増大のための方法

Also Published As

Publication number Publication date
CN1496260A (zh) 2004-05-12
US6750234B2 (en) 2004-06-15
CA2437844A1 (en) 2002-09-19
DE60229041D1 (de) 2008-11-06
US20020128298A1 (en) 2002-09-12
CA2437844C (en) 2007-05-15
EP1365762B1 (en) 2008-09-24
CN1265792C (zh) 2006-07-26
ATE409037T1 (de) 2008-10-15
JP5057353B2 (ja) 2012-10-24
MXPA03008096A (es) 2005-10-05
WO2002072092A1 (en) 2002-09-19
PT1365762E (pt) 2008-11-27
US20040198776A1 (en) 2004-10-07
JP2004519488A (ja) 2004-07-02
EP1365762A1 (en) 2003-12-03
ES2315358T3 (es) 2009-04-01
EP1365762A4 (en) 2005-05-25
HK1065941A1 (en) 2005-03-11

Similar Documents

Publication Publication Date Title
DK1365762T3 (da) Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
BRPI0416909A (pt) método de tratamento de aterosclerose
IS8395A (is) Fjölvasýklískar karboxýlsýrur og asýlsúlfónamíð sem hindrar á lifrabólgu C eftirmyndun
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
IL217623A (en) Amino-carbonyl-boron compound is converted
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
SE0301886D0 (sv) New use V
WO2007112000A3 (en) Treatment of pain
ATE319440T1 (de) Antidiabetische mittel
WO2005030120A3 (en) Antiangiogenic agents
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
TW200503668A (en) Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
DK1603577T3 (da) Forbindelser til behandling af smerte
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
DE69825154D1 (de) Pyridazinone als inhibitoren von cyclooxygenase-2
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
DE60231050D1 (de) Verwendung von Totarol zur Behandlung von Pruritus
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
AP2001002248A0 (en) Method for treating COPD.
SE0004101D0 (sv) New use
NZ519722A (en) Treatment of diabetic ulcers
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions